Betaine alleviates letrozole-induced polycystic ovarian syndrome in rats by regulating oxidative stress and inflammation and restoring the proliferation-apoptosis balance
Abstract
BACKGROUND: Polycystic ovarian syndrome (PCOS) is a common reproductive disorder that often leads to infertility. This study aimed to examine the potential beneficial effects of betaine (BTN) in a rat model of letrozole-induced PCOS.
METHODS: Thirty-six adult female rats were allocated to six groups (n = 6): control, BTN 100 (100 mg/kg/day BTN), PCOS (1 mg/kg/day letrozole), PCOS + BTN 50 (1 mg/kg/day letrozole + 50 mg/kg/day BTN), PCOS + BTN 100 (1 mg/kg/day letrozole + 100 mg/kg/day BTN), and PCOS + Metformin (Met) (1 mg/kg/day letrozole + 300 mg/kg/day Met). Letrozole was administered orally for 21 days, followed by 14 days of oral BTN or Met treatment.
RESULTS: Our findings indicated that BTN significantly ameliorated fasting blood glucose levels, insulin resistance, ovarian histopathological changes, and fibrosis in rats with PCOS. Reduced follicle-stimulating hormone (FSH) concentration, elevated luteinizing hormone (LH) levels, and an increased LH/FSH ratio were all alleviated in the BTN-treated PCOS rats. Moreover, BTN significantly diminished ovarian oxidative stress, as evidenced by elevated catalase and glutathione peroxidase activities, upregulated nuclear factor erythroid 2-related factor 2 (Nrf2) expression, and reduced malondialdehyde levels. Betaine markedly suppressed PCOS-induced inflammation by downregulating phosphorylated p38 mitogen-activated protein kinase (p38 MAPK) and nuclear factor-kappa B p65 (NF-κB p65). The disrupted proliferation-apoptosis…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.